Recommended injection cycles and treatment courses for bicizumab

Bimekizumab (Bimekizumab) is a high-affinity dual-targeted antibody. Its injection regimen for the treatment of plaque psoriasis is different from otherIL-17 pathway biologics. It pays more attention to the balance between rapid onset of effect in the early stage and maintenance of efficacy in the later stage. The recommended dose of bicizumab is 320 mg per injection, usually administered as two 160 mg injections. At the beginning of treatment, it is recommended to give one injection at weeks 0, 4, 8, 12 and 16 weeks to form an intensive course of treatment to quickly inhibit the inflammatory response mediated by IL-17A and IL-17F.

After entering the maintenance period, patients with normal weight can adjust the injection frequency to once every 8 weeks, still 320mg each time. This interval can effectively maintain inflammation control and reduce compliance issues caused by injection frequency. For individuals with higher body weight (such as ≥120kg) or severe disease who are sensitive to inflammatory reactions, the study recommends adjusting the injection interval to once every 4 weeks after 16 weeks to maintain a more stable drug blood concentration and avoid recurrence of skin lesions.

There is currently no unified standard for the total length of treatment, but it is generally recommended to continue treatment for more than one year, especially for patients with refractory psoriasis. Most clinicians flexibly adjust the medication cycle based on patient response and changes in skin symptoms. Some patients achieve long-term remission after half a year to one year of use. Some people can try to extend the injection interval or even stop taking the drug for observation, but this needs to be done under the guidance of a professional doctor. Long-term follow-up studies show that bicizumab not only takes effect quickly, but also has the ability to maintain skin remission for a long time. Its efficacy can still last for several months after stopping the drug, providing the possibility of chronic management.

Reference materials:https://www.drugs.com/bimekizumab.html